Curaleaf Launches Takeover Bid for Aurora Cannabis

Cross-Border Deal Structure

Curaleaf's bid represents the first post-rescheduling attempt by a U.S. MSO to acquire a Tier-1 Canadian LP. The company filed preliminary offer documents with the Ontario Securities Commission on August 23, 2026, according to regulatory filings. No purchase price. No share-exchange ratio. The initial submission left both undisclosed.

Timing aligns with renewed cross-border M&A interest following DEA's final rescheduling rule in March 2026, which moved cannabis from Schedule I to Schedule III and eliminated some—though not all—barriers to international capital flows for U.S. operators.

Aurora's Market Position

Aurora Cannabis operates cultivation facilities across Alberta, Ontario, and Denmark, with distribution agreements in 25 countries. The Edmonton-based company reported CAD $247 million in revenue for fiscal 2025, down 18% year-over-year, and posted a net loss of CAD $89 million in its most recent quarter.

Aurora's share price closed at CAD $1.42 on the Toronto Stock Exchange on August 22, giving the company a market capitalization of approximately CAD $312 million. The stock's declined 67% over the past three years as Canadian wholesale cannabis prices collapsed from CAD $6.23 per gram in 2021 to CAD $1.18 per gram in Q2 2026.

Curaleaf's Strategic Rationale

The acquisition would give Curaleaf immediate access to European medical-cannabis distribution channels and established cultivation infrastructure in low-cost jurisdictions. Curaleaf currently operates 135 dispensaries across 17 U.S. states and reported $1.3 billion in revenue for 2025, making it the second-largest MSO by sales behind Trulieve.

CEO Matt Darin has signaled international expansion as a 2026 priority. In a May earnings call, Darin said the company was evaluating "strategic opportunities in markets with federal frameworks" as U.S. interstate commerce remains prohibited under current DEA rules.

For full background on this story, see the CannIntel topic hub on the Curaleaf-Aurora takeover bid.

Regulatory and Tax Implications

The deal faces complex cross-border regulatory review, including approvals from Health Canada, the OSC, and potentially the Committee on Foreign Investment in the United States. Cannabis remains federally illegal in the U.S. under the Controlled Substances Act despite rescheduling to Schedule III. That creates jurisdictional ambiguity for transactions involving U.S. operators acquiring foreign assets.

Section 280E of the Internal Revenue Code still applies to U.S. cannabis businesses under Schedule III, barring deductions for cost of goods sold—but international subsidiaries operating outside U.S. jurisdiction may offer tax-planning opportunities that domestic acquisitions don't.

What Happens Next

Aurora's board has 30 days under Ontario securities law to formally respond to the unsolicited offer. Accept, reject, or solicit competing bids. Those are the options during that window. Aurora hasn't issued a public statement as of Sunday evening.

Curaleaf must file a full offer circular within 35 days, disclosing pricing, financing sources, and conditions precedent, and the transaction would require approval from at least two-thirds of Aurora shareholders if it proceeds to a vote.

We'll be watching three indicators: Aurora's board response by late September, Curaleaf's financing structure (equity, debt, or stock swap), and whether competing bids emerge from other Canadian LPs seeking scale.